Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Allergol Int ; 61(4): 597-607, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22918214

RESUMO

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic and eczematous skin lesions. In this study, AD-like disease was induced in NC/Nga mice so as to evaluate the anti-allergic effects of Vernonia amygdalina leaf extracts (VAM). METHODS: Forty NC/Nga mice were purchased for each of the two protocols (prophylactic and curative) of the study. Mice were randomly divided in groups of five or six after sensitization with 5% trinitrochlorobenzene (TNCB): aqueous extracts (VAM1), methanolic extracts (VAM2), hydrocortisone (HCT), buffer for the control (TNCB) and the normal mice (NORM) groups. RESULTS: As for HCT, VAM1 and VAM2-pretreated mice showed significantly lower number of scratching behavior episodes (p < 0.01; vs. TNCB) following TNCB challenge. In addition, VAM1, VAM2 exerted a significant inhibitory effect on the development of AD skin symptoms (vs. TNCB group; p < 0.001), the production of IgE, TNF-alpha (p < 0.05), IL-5 and IFN-gamma (p < 0.01) (vs. TNCB group) and on the increase in ear thickness (p < 0.05) in prophylactic protocol. In the AD curative protocol, topical VAM1, VAM2 markedly improved skin lesions such as erythema/hemorrhage (p < 0.05), scaling/dryness, erosion/excoriation (p < 0.01) (vs. TNCB mice). Furthermore, a significant decrease in ear thickness was noted in VAM1, VAM2, HCT groups (vs. TNCB group; p < 0.05) as well as the serum total IgE, MCP-1 (p < 0.01) and eotaxin (p < 0.05). VAM2 also improved chronic eczema dermatitis skin symptoms in a patient. CONCLUSIONS: Results from this report suggest that VAM extracts, known as ERK pathway inhibitor, prevent and improve atopic/eczema dermatitis syndrome.


Assuntos
Antialérgicos/farmacologia , Dermatite Atópica/imunologia , Extratos Vegetais/farmacologia , Folhas de Planta/química , Vernonia/química , Administração Tópica , Adolescente , Animais , Antialérgicos/administração & dosagem , Antialérgicos/uso terapêutico , Quimiocina CCL2/sangue , Quimiocina CCL2/imunologia , Citocinas/sangue , Citocinas/imunologia , Dermatite Atópica/induzido quimicamente , Dermatite Atópica/tratamento farmacológico , Modelos Animais de Doenças , Orelha/patologia , Eczema/tratamento farmacológico , Haptenos/efeitos adversos , Humanos , Imunoglobulina E/sangue , Imunoglobulina E/imunologia , Masculino , Camundongos , Extratos Vegetais/administração & dosagem , Extratos Vegetais/uso terapêutico , Pele/efeitos dos fármacos , Pele/imunologia , Pele/patologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...